Press coverage about GW Pharmaceuticals PLC- (NASDAQ:GWPH) has trended positive on Tuesday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. GW Pharmaceuticals PLC- earned a news sentiment score of 0.33 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.230614637157 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs… (culthub.com)
- GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs Raising Gross Proceeds of $ (nasdaq.com)
- GW Pharmaceuticals plc Announces the Closing of Public Offering … – GlobeNewswire (press release) (globenewswire.com)
- GW Pharmaceuticals PLC- (GWPH) and Its Competitors Financial Survey (americanbankingnews.com)
- Analysts Issue Forecasts for GW Pharmaceuticals PLC-‘s FY2018 Earnings (GWPH) (americanbankingnews.com)
Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) traded down $0.23 on Tuesday, reaching $122.32. 270,309 shares of the company were exchanged, compared to its average volume of 330,876. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.59 and a quick ratio of 7.47. GW Pharmaceuticals PLC- has a 12-month low of $92.65 and a 12-month high of $136.95.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.